Original Research ARTICLE
Comparative analysis of peptidoglycans from Pseudomonas aeruginosa strains isolated from chronic vs acute infections
- 1Instituto de Investigación Sanitaria de Palma (IdISPa), Spain
Pseudomonas aeruginosa is one of the first causes of acute nosocomial and chronic infections in patients with underlying respiratory pathologies such as cystic fibrosis (CF). It has been proposed that P. aeruginosa accumulates mutations driving to peptidoglycan modifications throughout the development of the CF-associated infection, as a strategy to lower the immune detection hence ameliorating the chronic persistence. As well, some studies dealing with peptidoglycan modifications driving to a better survival within the host have been published in other gram-negatives. According to these facts, the gram-negative peptidoglycan could be considered as a pathogen-associated molecular pattern with very important implications regarding the host’s detection-response, worthy to dissect in detail. For this reason, in this work we characterized for the first time the peptidoglycans of three large collections [early CF, late CF and acute infection (bloodstream) P. aeruginosa strains] from qualitative (HPLC), quantitative and inflammatory capacity-related perspectives. The final goal was to identify composition trends potentially supporting the cited strategy of evasion/resistance to the immune system and providing information regarding the differential intrinsic adaptation depending on the type of infection. Although we found several punctual strain-specific particularities, our results indicated a high degree of inter-collection uniformity in the peptidoglycan-related features and the absence of trends amongst the strains studied here. These results suggest that the peptidoglycan of P. aeruginosa is a notably conserved structure in natural isolates regardless of transitory changes that some external conditions could force. Finally, the inverse correlation between the relative amount of stem pentapeptides within the murein sacculus and the resistance to immune lytic attacks against the peptidoglycan was also suggested by our results. Altogether, this work is a major step ahead to understand the biology of peptidoglycan from P. aeruginosa natural strains, hopefully useful in future for therapeutic alternatives design.
Keywords: Pseudomonas aeruginosa, Peptidoglycan, HPLC, Clinical strains, Cystic Fibrosis, Bacteremia
Received: 13 Jun 2019;
Accepted: 29 Jul 2019.
Edited by:Axel Cloeckaert, Institut National de la Recherche Agronomique (INRA), France
Reviewed by:Mijoon Lee, University of Notre Dame, United States
Marina Borisova, University of Tübingen, Germany
Anthony J. Clarke, University of Guelph, Canada
Copyright: © 2019 Torrens, Escobar-Salom, Pol-Pol, Camps-Munar, Cabot, Lopez-Causape, Rojo-Molinero, Oliver and Juan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Carlos Juan, Instituto de Investigación Sanitaria de Palma (IdISPa), Palma, 07120, Spain, email@example.com